{"gene":"MAPT","run_date":"2026-06-10T02:59:50","timeline":{"discoveries":[{"year":1998,"finding":"FTDP-17 missense mutations in tau (e.g., G272V, P301L, V337M, R406W, E10+16) reduce the ability of recombinant tau to bind microtubules and promote microtubule assembly, with different mutations differentially altering biochemical properties and stoichiometry of brain tau isoforms.","method":"Functional assays of recombinant tau proteins (microtubule binding and assembly assays); biochemical analysis of soluble and insoluble tau from FTDP-17 patient brains","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution assays with recombinant mutant tau proteins combined with patient brain biochemistry; replicated across multiple mutations and multiple subsequent studies","pmids":["9836646"],"is_preprint":false},{"year":2000,"finding":"FTDP-17 mutations either reduce tau's ability to interact with microtubules or increase production of tau isoforms with four microtubule-binding repeats (4R tau); several missense mutations also stimulate heparin-induced tau filament formation in vitro, suggesting a gain of toxic function.","method":"In vitro microtubule binding assays, in vitro tau filament assembly assays with heparin, isoform ratio analysis","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution, replicated across multiple labs and consistent with PMID 9836646","pmids":["10899436"],"is_preprint":false},{"year":1999,"finding":"3R and 4R tau isoforms aggregate into distinct filament morphologies in different tauopathies: all six isoforms in Alzheimer's disease PHFs; only 4R tau in CBD and PSP (twisted/straight filaments); only 3R tau in Pick's disease (random coiled filaments), demonstrating isoform-specific filament assembly.","method":"Biochemical fractionation and immunoblotting of insoluble tau from tauopathy brains","journal":"Brain pathology","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic comparative biochemistry across multiple disease cohorts, independently replicated","pmids":["10517507"],"is_preprint":false},{"year":2001,"finding":"Using Xenopus oocyte maturation as a microtubule function assay, wild-type four-repeat tau inhibits maturation concentration-dependently while three-repeat tau has no effect. Five FTDP-17 mutants (G272V, ΔK280, P301L, P301S, V337M) failed to inhibit maturation, demonstrating reduced microtubule interaction; R406W behaved nearly like wild-type; S305N inhibited maturation more strongly than wild-type.","method":"Xenopus oocyte maturation assay with microinjected recombinant tau proteins","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — intact-cell functional assay with multiple mutants tested, single lab but multiple orthogonal readouts","pmids":["11756436"],"is_preprint":false},{"year":2006,"finding":"FTDP-17 mutations G272V, ΔK280, and P301L markedly reduce tau's ability to regulate microtubule dynamic instability in living cells, while R406W (outside the microtubule-binding domain) does not significantly alter this regulation, consistent with a loss-of-function mechanism for most tau missense mutations.","method":"Microinjection of recombinant tau into cells expressing fluorescent tubulin; live-cell imaging of individual microtubule dynamic instability","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct in-cell functional assay with multiple mutants, orthogonal to in vitro binding assays","pmids":["16495230"],"is_preprint":false},{"year":1999,"finding":"FTDP-17 mutants V337M and R406W are less susceptible than P301L or wild-type tau to degradation by calpain I, with differences in accessibility of a cleavage site ~100 amino acids from the C-terminus, suggesting some FTDP-17 pathogenesis involves reduced proteolytic tau clearance.","method":"In vitro calpain I digestion assay of recombinant mutant tau proteins","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in vitro proteolysis assay, single lab, single method","pmids":["10561502"],"is_preprint":false},{"year":2016,"finding":"Increased neuronal activity (optogenetic and chemogenetic stimulation) stimulates tau release in vitro and enhances tau pathology in vivo; physiological tau released from donor cells can transfer to recipient cells via the extracellular space.","method":"Optogenetic and chemogenetic approaches in vitro and in vivo; conditioned medium transfer assay","journal":"Nature neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Moderate — two orthogonal activity-manipulation methods (optogenetic + chemogenetic), in vitro and in vivo validation, single lab","pmids":["27322420"],"is_preprint":false},{"year":2017,"finding":"Rab7A regulates tau secretion: deletion of Rab7A decreases tau secretion, while overexpression of dominant-negative Rab7A decreases and constitutively active Rab7A increases tau secretion. Partial co-localization of tau with Rab7A-positive late endosomal structures implicates late endosomes in tau secretion.","method":"Rab7A deletion and dominant-negative/constitutively active overexpression in cortical neurons and HeLa cells; tau secretion quantification; co-localization imaging","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function and gain-of-function experiments in two cell systems with imaging, single lab","pmids":["28222213"],"is_preprint":false},{"year":2019,"finding":"CAPON (carboxy-terminal PDZ ligand of nNOS) is a novel tau-binding protein identified by immunoprecipitation/LC-MS. CAPON overexpression induces higher levels of phosphorylated, oligomerized, and insoluble tau and causes caspase3-dependent neuronal death; CAPON deficiency ameliorates AD-related tau pathology.","method":"Immunoprecipitation/LC-MS tau interactome screen; CAPON overexpression and knockout in MAPT knock-in mice; biochemical fractionation; caspase3 assay","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — initial Co-IP/MS identification followed by in vivo genetic loss- and gain-of-function with defined cellular phenotypes","pmids":["31160584"],"is_preprint":false},{"year":2021,"finding":"TIA1 (RNA-binding protein) directly interacts with tau and drives its phase separation at physiological concentrations in the presence of RNA, without artificial crowding agents. Tau oligomers generated during TIA1 co-partitioning are significantly more toxic than aggregates formed with RNA alone or with crowding agents.","method":"In vitro phase separation assays with purified tau, RNA, and TIA1; toxicity assays comparing oligomers from different conditions","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution with purified components, multiple orthogonal assays (phase separation, oligomer formation, toxicity), single lab","pmids":["33619090"],"is_preprint":false},{"year":2018,"finding":"Hyperacetylation of tau by p300 histone acetyltransferase disfavors liquid-liquid phase separation (LLPS) of tau, inhibits heparin-induced aggregation, and impedes LLPS-initiated microtubule assembly, indicating that acetylation prevents LLPS-dependent aggregation but also causes loss-of-function in microtubule stabilization.","method":"In vitro acetylation by p300; LLPS assays; thioflavin T aggregation assay; microtubule assembly assay","journal":"International journal of molecular sciences","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with enzymatic modification and multiple functional readouts, single lab","pmids":["29734651"],"is_preprint":false},{"year":2022,"finding":"Aquaporin-4 (AQP4)-driven glymphatic clearance facilitates elimination of extracellular tau from brain to CSF and cervical lymph nodes. AQP4 deletion elevates tau in CSF and markedly exacerbates phosphorylated tau deposition and neurodegeneration in P301S tau transgenic mice.","method":"AQP4 knockout in P301S tau transgenic mice; tau quantification in CSF, interstitial fluid, and lymph nodes; immunohistochemistry for tau pathology and neurodegeneration markers","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic knockout with in vivo pathological readouts and CSF/lymph node tracking, single lab but multiple orthogonal methods","pmids":["35212707"],"is_preprint":false},{"year":2019,"finding":"In humanized MAPT knock-in mice expressing all six human tau isoforms, tau humanization significantly accelerates cell-to-cell propagation of AD brain-derived pathological tau, and pathological human tau interacts more efficiently with human tau than with murine tau, revealing species-specific differences in tau seeding.","method":"Homologous recombination knock-in; injection of AD brain-derived tau seeds; histological analysis of tau propagation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knock-in model with defined seeding experiments, cross-species comparison, in vivo propagation assay","pmids":["31273083"],"is_preprint":false},{"year":2020,"finding":"Oligodendroglial tau pathology propagates along white matter tracts independently of neuronal axons and results in oligodendrocyte cell loss. In contrast, astrocytic tau pathology requires neuronal tau for propagation, revealing cell-type-specific mechanisms of glial tau transmission.","method":"Neuronal tau knockdown mouse model; injection of CBD/PSP tau lysates; immunohistochemistry tracking glial tau spread and oligodendrocyte loss","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Moderate — novel genetic mouse model with neuronal tau knockdown, in vivo inoculation, defined cellular phenotype, single lab with multiple readouts","pmids":["31826239"],"is_preprint":false},{"year":2019,"finding":"BAG3, in cooperation with SYNPO (synaptopodin), facilitates autophagic clearance of phosphorylated tau (p-Ser262) in neuronal processes. Loss of either BAG3 or SYNPO impedes autophagosome-lysosome fusion predominantly in the post-synaptic compartment, leading to accumulation of p-Ser262 tau.","method":"shRNA knockdown of BAG3 and SYNPO in primary neurons; autophagy flux assay; immunofluorescence co-localization; biochemical fractionation","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function in primary neurons with specific phospho-tau readout, multiple methods, single lab","pmids":["30744518"],"is_preprint":false},{"year":2020,"finding":"Retromer component VPS35 depletion blocks autophagy resolution and causes marked accumulation of cytoplasmic tau aggregates; VPS35 overexpression has the opposite effect. The autophagy-lysosome axis is identified as the primary mode for clearance of aggregated tau species.","method":"Chemical and genetic (VPS35 knockdown/overexpression) approaches in cell models; tau aggregate quantification","journal":"Autophagy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — complementary loss- and gain-of-function with defined tau aggregate readout, single lab","pmids":["32960680"],"is_preprint":false},{"year":2013,"finding":"Tau oligomers (but not monomers) inhibit anterograde fast axonal transport (FAT) in a squid axoplasm assay; this inhibition requires a small N-terminal stretch termed the phosphatase-activation domain (PAD). Hsp70 preferentially binds tau oligomers and prevents their FAT inhibition.","method":"Squid axoplasm assay with monomeric vs. oligomeric/filamentous tau; PAD-deleted tau constructs; Hsp70 co-incubation","journal":"Biochemical Society transactions","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted in vitro axoplasm assay with domain-deletion analysis and chaperone rescue, single lab","pmids":["22817713"],"is_preprint":false},{"year":2018,"finding":"In-cell NMR in HEK-293T cells shows tau predominantly binds microtubules via its MT-binding repeats in the intracellular environment. Disease-associated phosphorylation of tau is rapidly dephosphorylated upon delivery into cells, suggesting an active cellular protection mechanism.","method":"In-cell NMR spectroscopy; immunofluorescence co-localization; comparison of in-cell spectrum to in vitro MT-bound tau spectrum","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — in-cell NMR is a rigorous structural method but single lab, single study","pmids":["30587819"],"is_preprint":false},{"year":2019,"finding":"Nuclear tau localizes to soluble and chromatin-bound fractions. Tau overexpression or detachment from microtubules increases VGluT1 gene expression. The FTDP-17 P301L mutation impairs this nuclear tau function, representing a loss-of-function mechanism affecting glutamatergic synaptic gene regulation.","method":"Subcellular fractionation; overexpression and microtubule-detachment experiments; qRT-PCR and western blot for VGluT1; P301L mutation comparison","journal":"Journal of molecular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — fractionation with functional gene expression readout, gain-of-function and mutation analysis, single lab","pmids":["30664870"],"is_preprint":false},{"year":2024,"finding":"Endocytosed tau fibrils accumulate in lysosomes of primary astrocytes and neurons, causing lysosomal swelling, deacidification, and ESCRT protein recruitment (but not Galectin-3) consistent with nanoscale membrane damage. Nucleation of cytosolic tau occurs predominantly at the lysosomal membrane, coupling lysosomal escape to cytosolic seeding.","method":"Live-cell imaging; STORM superresolution microscopy; ESCRT/Galectin-3 marker recruitment assays in primary cells","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Moderate — live imaging and superresolution microscopy in primary cells with multiple membrane-damage markers, single lab with orthogonal approaches","pmids":["38781206"],"is_preprint":false},{"year":2018,"finding":"Seed-competent tau monomer (Ms) adopts multiple stable conformational ensembles that each encode distinct tau strains. Ms from AD brain encodes a single strain; Ms from CBD brain encodes three sub-strains that each re-establish all three upon inoculation into cells. Tau monomer conformation thus determines strain identity.","method":"Tau monomer purification and inoculation into tau-reporter cell lines (DS9, DS10); inoculation into PS19 tauopathy mice; neuropathological readout","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 / Strong — cell-based strain propagation assay and in vivo inoculation in mouse model, human patient material, multiple disease sources tested","pmids":["30526844"],"is_preprint":false},{"year":2021,"finding":"Acetylmimetic mutations at K321Q and K353Q (KXGS motifs) in tau strongly inhibit prion-like seeded aggregation and intrinsic aggregation of pathogenic P301L/S320F tau double mutant, and alter tau conformational structure to impair Thioflavin S binding, while acetylmimetics at all KXGS sites decrease tau-microtubule interactions.","method":"HEK293T cell-based tau aggregation assay; microtubule binding assay; Thioflavin S staining; site-directed mutagenesis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based and in vitro functional assays with multiple site-specific acetylmimetics, single lab","pmids":["34426645"],"is_preprint":false},{"year":2024,"finding":"Tau undergoes liquid-liquid phase separation (LLPS) with DNA, mononucleosomes, and reconstituted nucleosome arrays; low concentrations of tau promote chromatin compaction and protect DNA from digestion. These interactions are driven by tau's binding to linker and nucleosomal DNA and are disrupted by tau hyperphosphorylation.","method":"In vitro LLPS assays; DNA protection/digestion assays; chromatin compaction assays; phosphorylation with kinases; NMR and biophysical characterization","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple chromatin substrates, enzymatic phosphorylation reversal, multiple orthogonal biophysical methods, single lab","pmids":["38429335"],"is_preprint":false},{"year":2023,"finding":"G3BP2, a core stress granule component, directly interacts with tau and inhibits tau aggregation by masking the microtubule-binding region (MTBR) of tau. Loss of G3BP2 in human neurons and brain organoids significantly elevates tau pathology; G3BP2-tau interaction is increased in multiple human tauopathies independent of NFT formation.","method":"Co-immunoprecipitation; G3BP2 knockdown in iPSC-derived neurons and brain organoids; in vitro aggregation assay; MTBR mapping; human tauopathy brain analysis","journal":"Neuron","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct interaction mapping, loss-of-function in human neurons and organoids, human disease brain validation, multiple orthogonal methods","pmids":["37385246"],"is_preprint":false},{"year":2013,"finding":"Hypoglycemia activates the AMPK-Akt-GSK3 pathway in neurons, leading to increased GSK3α/β activity and tau hyperphosphorylation at Ser262 and Ser396, both in differentiated N2a cells and in rat hippocampus following intracerebroventricular streptozotocin injection.","method":"Cell culture glucose deprivation; in vivo intracerebroventricular STZ injection; western blot for phospho-tau, phospho-GSK3, phospho-Akt, phospho-AMPK","journal":"Current Alzheimer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo models with pathway-specific readouts, single lab","pmids":["23036024"],"is_preprint":false},{"year":2014,"finding":"Tau-tubulin kinase 1 (TTBK1) directly phosphorylates tau, especially at Ser422, and activates CDK5. TTBK1 transgenic mice crossed with P301L tau mice show accelerated tau accumulation and neuroinflammation, and TTBK1 overexpression induces axonal degeneration in vitro.","method":"In vitro kinase assay; TTBK1 transgenic mouse cross with tau mutant mice; in vitro axonal degeneration assay","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro kinase assay plus in vivo transgenic mouse model, single lab","pmids":["24808823"],"is_preprint":false}],"current_model":"MAPT/tau is a microtubule-associated protein that stabilizes axonal microtubules via its repeat-domain binding, regulates microtubule dynamics, undergoes secretion via Rab7A/late endosomal pathway, spreads trans-synaptically in a neuronal activity-dependent manner, is cleared by the glymphatic system and autophagy-lysosome pathway (facilitated by BAG3/SYNPO and retromer/VPS35), undergoes extensive post-translational modifications (phosphorylation, acetylation) that control its microtubule binding, phase separation, chromatin interactions, and aggregation propensity, and can adopt distinct seed-competent monomer conformations that encode different tauopathy strains; disease-causing FTDP-17 mutations reduce microtubule regulatory function and/or shift 3R:4R isoform ratios, while tau oligomers inhibit axonal transport via an N-terminal phosphatase-activation domain and interact pathologically with partners such as TIA1, CAPON, and G3BP2."},"narrative":{"mechanistic_narrative":"MAPT encodes tau, a microtubule-associated protein whose primary physiological role is to bind and stabilize microtubules and regulate microtubule dynamic instability through its repeat-domain interactions [PMID:11756436, PMID:16495230, PMID:30587819]. In the intracellular environment tau associates predominantly with microtubules via its MT-binding repeats, and disease-associated phosphorylation is rapidly reversed by cellular activity [PMID:30587819]. Tau also performs nuclear functions, localizing to chromatin and regulating glutamatergic synaptic gene expression such as VGluT1 [PMID:30664870], and binding linker and nucleosomal DNA to drive chromatin compaction and protect DNA, interactions disrupted by hyperphosphorylation [PMID:38429335]. FTDP-17 missense mutations and isoform-shifting mutations act largely through loss of microtubule regulatory function or by shifting the 3R:4R isoform ratio, with several mutations additionally promoting filament assembly as a gain of toxic function [PMID:9836646, PMID:10899436, PMID:16495230]; isoform composition itself dictates filament morphology and disease identity, with all six isoforms in AD, 4R tau in CBD/PSP, and 3R tau in Pick's disease [PMID:10517507]. Post-translational modifications govern tau behavior: acetylation by p300 and acetylmimetics at KXGS motifs suppress phase separation and aggregation while impairing microtubule binding [PMID:29734651, PMID:34426645], and kinases including GSK3, TTBK1, and CDK5 drive pathogenic hyperphosphorylation linked to metabolic stress and neurodegeneration [PMID:23036024, PMID:24808823]. Tau undergoes liquid-liquid phase separation, which the RNA-binding protein TIA1 promotes in the presence of RNA to generate especially toxic oligomers [PMID:33619090]. Pathologically, tau adopts distinct seed-competent monomer conformations that encode separate tauopathy strains [PMID:30526844]; oligomers inhibit fast axonal transport through an N-terminal phosphatase-activation domain [PMID:22817713] and propagate trans-synaptically in an activity-dependent manner [PMID:27322420, PMID:31273083], with cell-type-specific glial transmission mechanisms [PMID:31826239]. Tau is secreted via a Rab7A-dependent late endosomal route [PMID:28222213] and cleared by glymphatic (AQP4-dependent) drainage and the autophagy-lysosome pathway facilitated by BAG3/SYNPO and retromer VPS35 [PMID:35212707, PMID:30744518, PMID:32960680]; endocytosed fibrils damage lysosomal membranes and nucleate cytosolic seeding at those membranes [PMID:38781206]. Additional binding partners CAPON and G3BP2 modulate tau aggregation and toxicity, with G3BP2 protecting tau by masking its microtubule-binding region [PMID:31160584, PMID:37385246].","teleology":[{"year":1998,"claim":"Established that FTDP-17 mutations cause disease by impairing tau's core microtubule-binding and assembly-promoting function, defining a loss-of-function axis for tau pathogenesis.","evidence":"Microtubule binding/assembly assays with recombinant mutant tau plus patient brain biochemistry","pmids":["9836646"],"confidence":"High","gaps":["Did not establish whether loss of MT function alone is sufficient for neurodegeneration","Did not resolve the gain-of-function aggregation contribution"]},{"year":1999,"claim":"Showed that isoform composition determines tauopathy-specific filament morphology, linking the 3R:4R balance to distinct diseases.","evidence":"Biochemical fractionation and immunoblotting of insoluble tau across AD, CBD, PSP, and Pick's disease brains","pmids":["10517507"],"confidence":"High","gaps":["Did not define the structural basis of isoform-specific assembly","Correlative across cohorts, not causal"]},{"year":1999,"claim":"Indicated that some FTDP-17 mutations alter tau proteolytic clearance, introducing degradation resistance as a possible pathogenic mechanism.","evidence":"In vitro calpain I digestion of recombinant mutant tau","pmids":["10561502"],"confidence":"Medium","gaps":["Single in vitro proteolysis assay, single lab","Cellular relevance of calpain cleavage site accessibility not tested"]},{"year":2000,"claim":"Unified the loss-of-function and gain-of-toxic-function views by showing mutations either reduce MT interaction or shift toward 4R tau while several also stimulate filament formation.","evidence":"In vitro MT binding, heparin-induced filament assembly, and isoform ratio analysis","pmids":["10899436"],"confidence":"High","gaps":["Heparin-induced assembly is non-physiological","Relative contribution of each mechanism in vivo unresolved"]},{"year":2001,"claim":"Confirmed in an intact-cell functional assay that most FTDP-17 mutants lose microtubule-regulatory activity, with mutation-specific exceptions (R406W near-normal, S305N hyperactive).","evidence":"Xenopus oocyte maturation assay with microinjected recombinant tau","pmids":["11756436"],"confidence":"High","gaps":["Oocyte maturation is an indirect proxy for neuronal MT function","Did not address aggregation"]},{"year":2006,"claim":"Directly demonstrated in living cells that FTDP-17 mutations impair tau regulation of microtubule dynamic instability, solidifying the loss-of-function model.","evidence":"Live-cell imaging of individual microtubule dynamics after recombinant tau microinjection","pmids":["16495230"],"confidence":"High","gaps":["Non-neuronal cell context","Did not connect dynamics defect to downstream neuronal phenotype"]},{"year":2013,"claim":"Identified the N-terminal phosphatase-activation domain (PAD) as the element by which tau oligomers, but not monomers, inhibit fast axonal transport, defining a discrete toxic mechanism reversible by Hsp70.","evidence":"Squid axoplasm transport assay with monomer/oligomer and PAD-deletion constructs, plus Hsp70 rescue","pmids":["22817713"],"confidence":"High","gaps":["Invertebrate axoplasm system","PAD-dependent phosphatase activation not mapped to specific kinase/motor steps in mammalian neurons"]},{"year":2013,"claim":"Linked metabolic stress to tau hyperphosphorylation by showing hypoglycemia activates AMPK-Akt-GSK3 signaling to phosphorylate tau at disease sites.","evidence":"Glucose deprivation in N2a cells and ICV streptozotocin in rat hippocampus with phospho-specific blotting","pmids":["23036024"],"confidence":"Medium","gaps":["Single lab","Causal link from GSK3 activity to tau pathology not established by intervention"]},{"year":2014,"claim":"Established TTBK1 as a direct tau kinase that also activates CDK5 and accelerates tau pathology in vivo, adding a kinase node to tau hyperphosphorylation.","evidence":"In vitro kinase assay, TTBK1×P301L transgenic cross, in vitro axonal degeneration","pmids":["24808823"],"confidence":"Medium","gaps":["Single lab","TTBK1 overexpression may not reflect endogenous activity levels"]},{"year":2016,"claim":"Demonstrated that neuronal activity drives tau release and trans-synaptic transfer, providing a physiological trigger for pathological spread.","evidence":"Optogenetic and chemogenetic stimulation in vitro and in vivo with conditioned-medium transfer","pmids":["27322420"],"confidence":"High","gaps":["Molecular release machinery not defined here","Did not establish which tau species transfers"]},{"year":2017,"claim":"Defined a Rab7A-dependent late endosomal route for tau secretion, identifying machinery for tau export.","evidence":"Rab7A deletion and dominant-negative/constitutively-active overexpression with secretion quantification and co-localization in neurons and HeLa cells","pmids":["28222213"],"confidence":"Medium","gaps":["Single lab","Partial co-localization leaves other secretion routes open"]},{"year":2018,"claim":"Resolved how acetylation tunes tau, showing p300 hyperacetylation blocks LLPS and aggregation but causes loss of microtubule-stabilizing function.","evidence":"In vitro p300 acetylation with LLPS, ThT aggregation, and MT assembly readouts","pmids":["29734651"],"confidence":"High","gaps":["In vitro only","Site-resolved acetylation effects not mapped here"]},{"year":2018,"claim":"Used in-cell NMR to show tau binds microtubules via its repeats in the native cellular environment and that disease phosphorylation is actively reversed, implying a cellular protection mechanism.","evidence":"In-cell NMR in HEK-293T with immunofluorescence and comparison to in vitro MT-bound spectra","pmids":["30587819"],"confidence":"Medium","gaps":["Single lab/study","Non-neuronal cells; dephosphorylating enzymes not identified"]},{"year":2018,"claim":"Established that seed-competent tau monomer conformation encodes tauopathy strain identity, reframing strains as monomer-level conformational information.","evidence":"Monomer purification and inoculation into reporter cell lines and PS19 mice using human AD and CBD material","pmids":["30526844"],"confidence":"High","gaps":["Structural basis of distinct monomer ensembles not determined","Mechanism converting monomer conformation to strain not resolved"]},{"year":2019,"claim":"Identified nuclear/chromatin-bound tau as a regulator of glutamatergic synaptic gene expression (VGluT1) impaired by P301L, defining a nuclear loss-of-function mechanism.","evidence":"Subcellular fractionation, MT-detachment/overexpression, qRT-PCR with P301L comparison","pmids":["30664870"],"confidence":"Medium","gaps":["Mechanism of tau-driven transcriptional regulation unclear","Single lab"]},{"year":2019,"claim":"Identified CAPON as a tau-binding protein whose levels drive phosphorylation, oligomerization, and caspase-3-dependent neuronal death, with deficiency ameliorating pathology.","evidence":"IP/LC-MS interactome plus CAPON overexpression and knockout in MAPT knock-in mice","pmids":["31160584"],"confidence":"High","gaps":["Direct vs indirect binding interface not mapped","Mechanism linking CAPON to tau phosphorylation unresolved"]},{"year":2019,"claim":"Showed humanization of tau accelerates seeded propagation and that human pathological tau seeds human tau more efficiently, revealing species-specific seeding determinants.","evidence":"Humanized MAPT knock-in mice injected with AD brain-derived tau seeds","pmids":["31273083"],"confidence":"High","gaps":["Sequence determinants of species specificity not pinpointed","Did not resolve which isoforms drive efficiency"]},{"year":2019,"claim":"Established BAG3/SYNPO-mediated autophagic clearance of phospho-Ser262 tau in post-synaptic compartments, linking autophagosome-lysosome fusion to tau homeostasis.","evidence":"shRNA knockdown of BAG3 and SYNPO in primary neurons with autophagy flux and co-localization assays","pmids":["30744518"],"confidence":"Medium","gaps":["Single lab","Selectivity for p-Ser262 tau over other species not fully defined"]},{"year":2020,"claim":"Revealed cell-type-specific glial tau transmission: oligodendroglial tau spreads independently of neurons whereas astrocytic tau requires neuronal tau.","evidence":"Neuronal tau knockdown mice injected with CBD/PSP lysates, tracked by immunohistochemistry","pmids":["31826239"],"confidence":"High","gaps":["Molecular basis of glial uptake/spread not defined","Single lab"]},{"year":2020,"claim":"Established the autophagy-lysosome axis as the primary route for clearing aggregated tau, with retromer VPS35 controlling autophagy resolution.","evidence":"VPS35 knockdown/overexpression and chemical autophagy modulation in cell models with aggregate quantification","pmids":["32960680"],"confidence":"Medium","gaps":["Cell-model only","Mechanistic link from retromer to autophagy resolution not detailed"]},{"year":2021,"claim":"Showed TIA1 directly drives physiological-concentration tau phase separation with RNA, generating oligomers more toxic than other aggregation routes, connecting RNP biology to tau toxicity.","evidence":"In vitro phase separation with purified tau, RNA, and TIA1 plus comparative toxicity assays","pmids":["33619090"],"confidence":"High","gaps":["In vitro reconstitution; cellular validation limited","Toxic oligomer species not structurally defined"]},{"year":2021,"claim":"Showed KXGS-motif acetylmimetics inhibit seeded and intrinsic aggregation and alter tau conformation while reducing MT binding, dissecting site-specific acetylation effects.","evidence":"HEK293T aggregation and MT binding assays with site-directed acetylmimetic mutants and ThS staining","pmids":["34426645"],"confidence":"Medium","gaps":["Acetylmimetics approximate but do not equal native acetylation","Single lab"]},{"year":2022,"claim":"Established AQP4-dependent glymphatic clearance as an in vivo route eliminating extracellular tau to CSF and lymph nodes, with loss exacerbating tau pathology.","evidence":"AQP4 knockout in P301S mice with tau tracking in CSF/ISF/lymph nodes and pathology readouts","pmids":["35212707"],"confidence":"High","gaps":["Did not define molecular form of tau cleared","Glymphatic vs cellular clearance contributions not partitioned"]},{"year":2023,"claim":"Identified G3BP2 as a direct tau partner that suppresses aggregation by masking the microtubule-binding region, with loss elevating tau pathology in human neurons and organoids.","evidence":"Co-IP, MTBR mapping, G3BP2 knockdown in iPSC neurons/organoids, in vitro aggregation, human tauopathy brain analysis","pmids":["37385246"],"confidence":"High","gaps":["Structural detail of MTBR masking not resolved","Regulation of G3BP2-tau interaction in disease unclear"]},{"year":2024,"claim":"Demonstrated that tau binds DNA, mononucleosomes, and nucleosome arrays via LLPS to compact chromatin and protect DNA, with hyperphosphorylation disrupting these chromatin functions.","evidence":"In vitro LLPS, DNA protection/digestion, chromatin compaction, enzymatic phosphorylation, and NMR/biophysics","pmids":["38429335"],"confidence":"High","gaps":["In vitro reconstitution; in vivo chromatin role not established","Genomic targets of nuclear tau not mapped"]},{"year":2024,"claim":"Showed endocytosed tau fibrils damage lysosomal membranes and nucleate cytosolic seeding at those membranes, coupling lysosomal escape to seeding.","evidence":"Live-cell and STORM imaging with ESCRT/Galectin-3 markers in primary astrocytes and neurons","pmids":["38781206"],"confidence":"High","gaps":["Molecular trigger of membrane permeabilization not defined","Single lab"]},{"year":null,"claim":"How tau's physiological microtubule, nuclear/chromatin, and phase-separation functions are coordinately lost and converted into strain-specific seed-competent aggregates in disease remains unresolved at the structural and pathway-integration level.","evidence":"","pmids":[],"confidence":"High","gaps":["No structural mechanism linking monomer conformational ensembles to specific clinical strains","Integration of secretion, glymphatic, and autophagic clearance routes in vivo not quantified","Causal hierarchy among phosphorylation, acetylation, and aggregation not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[3,4,17]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[22]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[18]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[3,4,17]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[18,22]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[22]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[7]},{"term_id":"GO:0005764","term_label":"lysosome","supporting_discovery_ids":[19]},{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[6,11]}],"pathway":[{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[14,15]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[7]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,1,2]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[22]}],"complexes":[],"partners":["TIA1","CAPON","G3BP2","RAB7A","BAG3","SYNPO","VPS35","TTBK1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P10636","full_name":"Microtubule-associated protein tau","aliases":["Neurofibrillary tangle protein","Paired helical filament-tau","PHF-tau"],"length_aa":758,"mass_kda":78.9,"function":"Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity (PubMed:21985311). The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both (PubMed:21985311, PubMed:32961270). Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization","subcellular_location":"Cytoplasm, cytosol; Cell membrane; Cytoplasm, cytoskeleton; Cell projection, axon; Cell projection, dendrite; Secreted","url":"https://www.uniprot.org/uniprotkb/P10636/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/MAPT","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/MAPT","total_profiled":1310},"omim":[{"mim_id":"621246","title":"TRAB DOMAIN-CONTAINING PROTEIN; TRABD","url":"https://www.omim.org/entry/621246"},{"mim_id":"619415","title":"TAU TUBULIN KINASE 1; TTBK1","url":"https://www.omim.org/entry/619415"},{"mim_id":"619132","title":"FRONTOTEMPORAL DEMENTIA AND/OR AMYOTROPHIC LATERAL SCLEROSIS 8; FTDALS8","url":"https://www.omim.org/entry/619132"},{"mim_id":"618093","title":"SPINOCEREBELLAR ATAXIA 48; SCA48","url":"https://www.omim.org/entry/618093"},{"mim_id":"616840","title":"PARKINSON DISEASE 23, AUTOSOMAL RECESSIVE EARLY-ONSET; PARK23","url":"https://www.omim.org/entry/616840"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Plasma membrane","reliability":"Supported"},{"location":"End piece","reliability":"Supported"},{"location":"Nuclear speckles","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":147.9},{"tissue":"skeletal muscle","ntpm":83.6}],"url":"https://www.proteinatlas.org/search/MAPT"},"hgnc":{"alias_symbol":["MTBT1","tau","PPND","FTDP-17","TAU","MSTD","MTBT2","FLJ31424","MGC138549","PPP1R103","tau-40","Tau-PHF6"],"prev_symbol":["DDPAC","MAPTL"]},"alphafold":{"accession":"P10636","domains":[],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P10636","model_url":"https://alphafold.ebi.ac.uk/files/AF-P10636-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P10636-F1-predicted_aligned_error_v6.png","plddt_mean":49.22},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=MAPT","jax_strain_url":"https://www.jax.org/strain/search?query=MAPT"},"sequence":{"accession":"P10636","fasta_url":"https://rest.uniprot.org/uniprotkb/P10636.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P10636/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P10636"}},"corpus_meta":[{"pmid":"9836646","id":"PMC_9836646","title":"Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17.","date":"1998","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/9836646","citation_count":809,"is_preprint":false},{"pmid":"21555069","id":"PMC_21555069","title":"The many faces of tau.","date":"2011","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/21555069","citation_count":682,"is_preprint":false},{"pmid":"27322420","id":"PMC_27322420","title":"Neuronal activity enhances tau propagation and tau pathology in vivo.","date":"2016","source":"Nature neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27322420","citation_count":656,"is_preprint":false},{"pmid":"27615390","id":"PMC_27615390","title":"Tau and tauopathies.","date":"2016","source":"Brain research bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/27615390","citation_count":461,"is_preprint":false},{"pmid":"21720721","id":"PMC_21720721","title":"Neuropathology of frontotemporal lobar degeneration-tau (FTLD-tau).","date":"2011","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/21720721","citation_count":310,"is_preprint":false},{"pmid":"10517507","id":"PMC_10517507","title":"Comparative biochemistry of tau in progressive supranuclear palsy, corticobasal degeneration, FTDP-17 and Pick's disease.","date":"1999","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/10517507","citation_count":305,"is_preprint":false},{"pmid":"33488497","id":"PMC_33488497","title":"Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation.","date":"2021","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33488497","citation_count":279,"is_preprint":false},{"pmid":"15365985","id":"PMC_15365985","title":"The role of tau (MAPT) in frontotemporal dementia and related tauopathies.","date":"2004","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/15365985","citation_count":277,"is_preprint":false},{"pmid":"30767766","id":"PMC_30767766","title":"A walk through tau therapeutic strategies.","date":"2019","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/30767766","citation_count":214,"is_preprint":false},{"pmid":"35212707","id":"PMC_35212707","title":"Glymphatic system clears extracellular tau and protects from tau aggregation and neurodegeneration.","date":"2022","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35212707","citation_count":208,"is_preprint":false},{"pmid":"22817713","id":"PMC_22817713","title":"Tau oligomers and tau toxicity in neurodegenerative disease.","date":"2012","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/22817713","citation_count":182,"is_preprint":false},{"pmid":"30529601","id":"PMC_30529601","title":"Biomarkers for tau pathology.","date":"2018","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/30529601","citation_count":175,"is_preprint":false},{"pmid":"29951497","id":"PMC_29951497","title":"Tau in neurodegenerative disease.","date":"2018","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29951497","citation_count":164,"is_preprint":false},{"pmid":"31273083","id":"PMC_31273083","title":"Humanization of the entire murine Mapt gene provides a murine model of pathological human tau propagation.","date":"2019","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31273083","citation_count":161,"is_preprint":false},{"pmid":"28558799","id":"PMC_28558799","title":"Propagation of Tau aggregates.","date":"2017","source":"Molecular brain","url":"https://pubmed.ncbi.nlm.nih.gov/28558799","citation_count":156,"is_preprint":false},{"pmid":"12470988","id":"PMC_12470988","title":"Tau gene mutations: dissecting the pathogenesis of FTDP-17.","date":"2002","source":"Trends in molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12470988","citation_count":150,"is_preprint":false},{"pmid":"20149808","id":"PMC_20149808","title":"Tau protein and tau aggregation inhibitors.","date":"2010","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20149808","citation_count":148,"is_preprint":false},{"pmid":"29734651","id":"PMC_29734651","title":"Acetylation Disfavors Tau Phase Separation.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29734651","citation_count":146,"is_preprint":false},{"pmid":"30605723","id":"PMC_30605723","title":"It's all about tau.","date":"2018","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/30605723","citation_count":143,"is_preprint":false},{"pmid":"15036206","id":"PMC_15036206","title":"Tau protein and neurodegeneration.","date":"2004","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15036206","citation_count":135,"is_preprint":false},{"pmid":"22482453","id":"PMC_22482453","title":"Tau and tauopathies.","date":"2012","source":"Progress in molecular biology and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/22482453","citation_count":133,"is_preprint":false},{"pmid":"10899436","id":"PMC_10899436","title":"Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease.","date":"2000","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/10899436","citation_count":131,"is_preprint":false},{"pmid":"26729186","id":"PMC_26729186","title":"Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.","date":"2016","source":"Drugs","url":"https://pubmed.ncbi.nlm.nih.gov/26729186","citation_count":126,"is_preprint":false},{"pmid":"18413467","id":"PMC_18413467","title":"Refining frontotemporal dementia with parkinsonism linked to chromosome 17: introducing FTDP-17 (MAPT) and FTDP-17 (PGRN).","date":"2008","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/18413467","citation_count":122,"is_preprint":false},{"pmid":"33619090","id":"PMC_33619090","title":"TIA1 potentiates tau phase separation and promotes generation of toxic oligomeric tau.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33619090","citation_count":122,"is_preprint":false},{"pmid":"29253099","id":"PMC_29253099","title":"Retiring the term FTDP-17 as MAPT mutations are genetic forms of sporadic frontotemporal tauopathies.","date":"2018","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29253099","citation_count":118,"is_preprint":false},{"pmid":"33418848","id":"PMC_33418848","title":"Tau Oligomers Neurotoxicity.","date":"2021","source":"Life (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33418848","citation_count":113,"is_preprint":false},{"pmid":"31997800","id":"PMC_31997800","title":"Toxic tau: structural origins of tau aggregation in Alzheimer's disease.","date":"2020","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/31997800","citation_count":112,"is_preprint":false},{"pmid":"27877124","id":"PMC_27877124","title":"Tau Structures.","date":"2016","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27877124","citation_count":109,"is_preprint":false},{"pmid":"33830330","id":"PMC_33830330","title":"Tau strains shape disease.","date":"2021","source":"Acta neuropathologica","url":"https://pubmed.ncbi.nlm.nih.gov/33830330","citation_count":107,"is_preprint":false},{"pmid":"28833749","id":"PMC_28833749","title":"Amyloidogenesis of Tau protein.","date":"2017","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/28833749","citation_count":106,"is_preprint":false},{"pmid":"25031639","id":"PMC_25031639","title":"Acetylation: a new key to unlock tau's role in neurodegeneration.","date":"2014","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25031639","citation_count":105,"is_preprint":false},{"pmid":"10983715","id":"PMC_10983715","title":"Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).","date":"2000","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10983715","citation_count":103,"is_preprint":false},{"pmid":"15615636","id":"PMC_15615636","title":"Pathways of tau fibrillization.","date":"2005","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15615636","citation_count":103,"is_preprint":false},{"pmid":"12428808","id":"PMC_12428808","title":"Tau and axonopathy in neurodegenerative disorders.","date":"2002","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12428808","citation_count":102,"is_preprint":false},{"pmid":"29790176","id":"PMC_29790176","title":"Tau filaments in neurodegenerative diseases.","date":"2018","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/29790176","citation_count":100,"is_preprint":false},{"pmid":"20658984","id":"PMC_20658984","title":"Proteolytic processing of tau.","date":"2010","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/20658984","citation_count":100,"is_preprint":false},{"pmid":"11402146","id":"PMC_11402146","title":"Missense and splice site mutations in tau associated with FTDP-17: multiple pathogenic mechanisms.","date":"2001","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/11402146","citation_count":96,"is_preprint":false},{"pmid":"26572762","id":"PMC_26572762","title":"Tau imaging in neurodegenerative diseases.","date":"2015","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/26572762","citation_count":96,"is_preprint":false},{"pmid":"20658986","id":"PMC_20658986","title":"From tau phosphorylation to tau aggregation: what about neuronal death?","date":"2010","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/20658986","citation_count":88,"is_preprint":false},{"pmid":"10767321","id":"PMC_10767321","title":"Untangling tau-related dementia.","date":"2000","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10767321","citation_count":87,"is_preprint":false},{"pmid":"32434664","id":"PMC_32434664","title":"Resurrecting the Mysteries of Big Tau.","date":"2020","source":"Trends in neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/32434664","citation_count":87,"is_preprint":false},{"pmid":"30174587","id":"PMC_30174587","title":"Untangling Tau and Iron: Exploring the Interaction Between Iron and Tau in Neurodegeneration.","date":"2018","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/30174587","citation_count":86,"is_preprint":false},{"pmid":"36499709","id":"PMC_36499709","title":"Tau Isoforms: Gaining Insight into MAPT Alternative Splicing.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36499709","citation_count":85,"is_preprint":false},{"pmid":"31160584","id":"PMC_31160584","title":"Tau binding protein CAPON induces tau aggregation and neurodegeneration.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31160584","citation_count":81,"is_preprint":false},{"pmid":"16495230","id":"PMC_16495230","title":"FTDP-17 mutations compromise the ability of tau to regulate microtubule dynamics in cells.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16495230","citation_count":81,"is_preprint":false},{"pmid":"31826239","id":"PMC_31826239","title":"Human tau pathology transmits glial tau aggregates in the absence of neuronal tau.","date":"2020","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31826239","citation_count":81,"is_preprint":false},{"pmid":"23535147","id":"PMC_23535147","title":"Anesthesia and tau pathology.","date":"2013","source":"Progress in neuro-psychopharmacology & biological psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/23535147","citation_count":79,"is_preprint":false},{"pmid":"30744518","id":"PMC_30744518","title":"BAG3 and SYNPO (synaptopodin) facilitate phospho-MAPT/Tau degradation via autophagy in neuronal processes.","date":"2019","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/30744518","citation_count":77,"is_preprint":false},{"pmid":"23772223","id":"PMC_23772223","title":"What Renders TAU Toxic.","date":"2013","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23772223","citation_count":71,"is_preprint":false},{"pmid":"19075586","id":"PMC_19075586","title":"Tau oligomerization: a role for tau aggregation intermediates linked to neurodegeneration.","date":"2008","source":"Current Alzheimer research","url":"https://pubmed.ncbi.nlm.nih.gov/19075586","citation_count":68,"is_preprint":false},{"pmid":"23882258","id":"PMC_23882258","title":"Characteristics of tau oligomers.","date":"2013","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23882258","citation_count":67,"is_preprint":false},{"pmid":"23948895","id":"PMC_23948895","title":"Tauopathies and tau oligomers.","date":"2013","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/23948895","citation_count":66,"is_preprint":false},{"pmid":"30526844","id":"PMC_30526844","title":"Tau monomer encodes strains.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30526844","citation_count":62,"is_preprint":false},{"pmid":"12446970","id":"PMC_12446970","title":"Tau, where are we now?","date":"2002","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/12446970","citation_count":61,"is_preprint":false},{"pmid":"34744602","id":"PMC_34744602","title":"Human Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration.","date":"2021","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34744602","citation_count":60,"is_preprint":false},{"pmid":"38781206","id":"PMC_38781206","title":"Tau fibrils induce nanoscale membrane damage and nucleate cytosolic tau at lysosomes.","date":"2024","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/38781206","citation_count":58,"is_preprint":false},{"pmid":"32047247","id":"PMC_32047247","title":"Bacterial DNA promotes Tau aggregation.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32047247","citation_count":57,"is_preprint":false},{"pmid":"24808823","id":"PMC_24808823","title":"Tau-tubulin kinase.","date":"2014","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/24808823","citation_count":56,"is_preprint":false},{"pmid":"34593302","id":"PMC_34593302","title":"Tau and MAPT genetics in tauopathies and synucleinopathies.","date":"2021","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/34593302","citation_count":54,"is_preprint":false},{"pmid":"25557050","id":"PMC_25557050","title":"The many faces of interferon tau.","date":"2015","source":"Amino acids","url":"https://pubmed.ncbi.nlm.nih.gov/25557050","citation_count":53,"is_preprint":false},{"pmid":"28222213","id":"PMC_28222213","title":"Rab7A regulates tau secretion.","date":"2017","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28222213","citation_count":52,"is_preprint":false},{"pmid":"20658996","id":"PMC_20658996","title":"Tau cleavage and tau aggregation in neurodegenerative disease.","date":"2010","source":"Biochemical Society transactions","url":"https://pubmed.ncbi.nlm.nih.gov/20658996","citation_count":51,"is_preprint":false},{"pmid":"11193179","id":"PMC_11193179","title":"Tau gene mutations in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Their relevance for understanding the neurogenerative process.","date":"2000","source":"Annals of the New York Academy of Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/11193179","citation_count":48,"is_preprint":false},{"pmid":"24050961","id":"PMC_24050961","title":"Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies.","date":"2013","source":"Neuropharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/24050961","citation_count":48,"is_preprint":false},{"pmid":"26551002","id":"PMC_26551002","title":"Tau Immunotherapy.","date":"2015","source":"Neuro-degenerative diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26551002","citation_count":47,"is_preprint":false},{"pmid":"38073060","id":"PMC_38073060","title":"Tau and neurodegeneration.","date":"2023","source":"Cytoskeleton (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/38073060","citation_count":45,"is_preprint":false},{"pmid":"35525497","id":"PMC_35525497","title":"Tau Aggregation.","date":"2022","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35525497","citation_count":44,"is_preprint":false},{"pmid":"2135393","id":"PMC_2135393","title":"Tau protein and neurodegeneration.","date":"1990","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/2135393","citation_count":43,"is_preprint":false},{"pmid":"23036024","id":"PMC_23036024","title":"Hypoglycemia induces tau hyperphosphorylation.","date":"2013","source":"Current Alzheimer research","url":"https://pubmed.ncbi.nlm.nih.gov/23036024","citation_count":43,"is_preprint":false},{"pmid":"11756436","id":"PMC_11756436","title":"Functional characterization of FTDP-17 tau gene mutations through their effects on Xenopus oocyte maturation.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11756436","citation_count":41,"is_preprint":false},{"pmid":"10561502","id":"PMC_10561502","title":"FTDP-17 tau mutations decrease the susceptibility of tau to calpain I digestion.","date":"1999","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/10561502","citation_count":40,"is_preprint":false},{"pmid":"18688097","id":"PMC_18688097","title":"Tau aggregates and tau pathology.","date":"2008","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/18688097","citation_count":39,"is_preprint":false},{"pmid":"35359226","id":"PMC_35359226","title":"Tau Toxicity in Neurodegeneration.","date":"2022","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/35359226","citation_count":38,"is_preprint":false},{"pmid":"10517508","id":"PMC_10517508","title":"Fibrillogenesis of tau: insights from tau missense mutations in FTDP-17.","date":"1999","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/10517508","citation_count":38,"is_preprint":false},{"pmid":"25950000","id":"PMC_25950000","title":"TTBK2: a tau protein kinase beyond tau phosphorylation.","date":"2015","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/25950000","citation_count":37,"is_preprint":false},{"pmid":"25822288","id":"PMC_25822288","title":"Azaphilones inhibit tau aggregation and dissolve tau aggregates in vitro.","date":"2015","source":"ACS chemical neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25822288","citation_count":37,"is_preprint":false},{"pmid":"17196872","id":"PMC_17196872","title":"Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation).","date":"2006","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/17196872","citation_count":36,"is_preprint":false},{"pmid":"17272893","id":"PMC_17272893","title":"Tau and tauopathies.","date":"2007","source":"Neurology India","url":"https://pubmed.ncbi.nlm.nih.gov/17272893","citation_count":35,"is_preprint":false},{"pmid":"31062171","id":"PMC_31062171","title":"14-3-3/Tau Interaction and Tau Amyloidogenesis.","date":"2019","source":"Journal of molecular neuroscience : MN","url":"https://pubmed.ncbi.nlm.nih.gov/31062171","citation_count":34,"is_preprint":false},{"pmid":"33571704","id":"PMC_33571704","title":"Tau internalization: A complex step in tau propagation.","date":"2021","source":"Ageing research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/33571704","citation_count":33,"is_preprint":false},{"pmid":"38429335","id":"PMC_38429335","title":"Phosphorylation regulates tau's phase separation behavior and interactions with chromatin.","date":"2024","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/38429335","citation_count":33,"is_preprint":false},{"pmid":"36378913","id":"PMC_36378913","title":"All the Tau We Cannot See.","date":"2022","source":"Annual review of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36378913","citation_count":32,"is_preprint":false},{"pmid":"32960680","id":"PMC_32960680","title":"Retromer regulates the lysosomal clearance of MAPT/tau.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/32960680","citation_count":31,"is_preprint":false},{"pmid":"36688478","id":"PMC_36688478","title":"Tau, tau kinases, and tauopathies: An updated overview.","date":"2023","source":"BioFactors (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/36688478","citation_count":29,"is_preprint":false},{"pmid":"32685100","id":"PMC_32685100","title":"Red Ginseng Inhibits Tau Aggregation and Promotes Tau Dissociation In Vitro.","date":"2020","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/32685100","citation_count":28,"is_preprint":false},{"pmid":"27543203","id":"PMC_27543203","title":"Pioglitazone prevents tau oligomerization.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27543203","citation_count":28,"is_preprint":false},{"pmid":"28790016","id":"PMC_28790016","title":"Tau-imaging in neurodegeneration.","date":"2017","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/28790016","citation_count":27,"is_preprint":false},{"pmid":"34426645","id":"PMC_34426645","title":"Tau K321/K353 pseudoacetylation within KXGS motifs regulates tau-microtubule interactions and inhibits aggregation.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/34426645","citation_count":27,"is_preprint":false},{"pmid":"30664870","id":"PMC_30664870","title":"Tau Modulates VGluT1 Expression.","date":"2019","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30664870","citation_count":26,"is_preprint":false},{"pmid":"23277060","id":"PMC_23277060","title":"Tau aggregates as immunotherapeutic targets.","date":"2013","source":"Frontiers in bioscience (Scholar edition)","url":"https://pubmed.ncbi.nlm.nih.gov/23277060","citation_count":26,"is_preprint":false},{"pmid":"28982935","id":"PMC_28982935","title":"The evolution of interferon-tau.","date":"2017","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/28982935","citation_count":25,"is_preprint":false},{"pmid":"12781592","id":"PMC_12781592","title":"Early and pre-symptomatic neuropsychological dysfunction in the PPND family with the N279K tau mutation.","date":"2003","source":"Parkinsonism & related disorders","url":"https://pubmed.ncbi.nlm.nih.gov/12781592","citation_count":25,"is_preprint":false},{"pmid":"24041111","id":"PMC_24041111","title":"Potential synergy between tau aggregation inhibitors and tau chaperone modulators.","date":"2013","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/24041111","citation_count":24,"is_preprint":false},{"pmid":"31793596","id":"PMC_31793596","title":"Xanthohumol inhibits tau protein aggregation and protects cells against tau aggregates.","date":"2019","source":"Food & function","url":"https://pubmed.ncbi.nlm.nih.gov/31793596","citation_count":24,"is_preprint":false},{"pmid":"37730697","id":"PMC_37730697","title":"Cancer-specific association between Tau (MAPT) and cellular pathways, clinical outcome, and drug response.","date":"2023","source":"Scientific data","url":"https://pubmed.ncbi.nlm.nih.gov/37730697","citation_count":24,"is_preprint":false},{"pmid":"30587819","id":"PMC_30587819","title":"In-Cell NMR Study of Tau and MARK2 Phosphorylated Tau.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30587819","citation_count":23,"is_preprint":false},{"pmid":"35765058","id":"PMC_35765058","title":"Reassessment of Neuronal Tau Distribution in Adult Human Brain and Implications for Tau Pathobiology.","date":"2022","source":"Acta neuropathologica communications","url":"https://pubmed.ncbi.nlm.nih.gov/35765058","citation_count":23,"is_preprint":false},{"pmid":"37385246","id":"PMC_37385246","title":"Increased G3BP2-Tau interaction in tauopathies is a natural defense against Tau aggregation.","date":"2023","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/37385246","citation_count":22,"is_preprint":false},{"pmid":"36232909","id":"PMC_36232909","title":"The Interplay between GSK3β and Tau Ser262 Phosphorylation during the Progression of Tau Pathology.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36232909","citation_count":22,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":40363,"output_tokens":6136,"usd":0.106565,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14926,"output_tokens":6942,"usd":0.12409,"stage2_stop_reason":"end_turn"},"total_usd":0.230655,"stage1_batch_id":"msgbatch_01BbTCMyrRPyhtEq6b1MdwCN","stage2_batch_id":"msgbatch_011dEed5bbxYvTAaQWKJevxu","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"FTDP-17 missense mutations in tau (e.g., G272V, P301L, V337M, R406W, E10+16) reduce the ability of recombinant tau to bind microtubules and promote microtubule assembly, with different mutations differentially altering biochemical properties and stoichiometry of brain tau isoforms.\",\n      \"method\": \"Functional assays of recombinant tau proteins (microtubule binding and assembly assays); biochemical analysis of soluble and insoluble tau from FTDP-17 patient brains\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution assays with recombinant mutant tau proteins combined with patient brain biochemistry; replicated across multiple mutations and multiple subsequent studies\",\n      \"pmids\": [\"9836646\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"FTDP-17 mutations either reduce tau's ability to interact with microtubules or increase production of tau isoforms with four microtubule-binding repeats (4R tau); several missense mutations also stimulate heparin-induced tau filament formation in vitro, suggesting a gain of toxic function.\",\n      \"method\": \"In vitro microtubule binding assays, in vitro tau filament assembly assays with heparin, isoform ratio analysis\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution, replicated across multiple labs and consistent with PMID 9836646\",\n      \"pmids\": [\"10899436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"3R and 4R tau isoforms aggregate into distinct filament morphologies in different tauopathies: all six isoforms in Alzheimer's disease PHFs; only 4R tau in CBD and PSP (twisted/straight filaments); only 3R tau in Pick's disease (random coiled filaments), demonstrating isoform-specific filament assembly.\",\n      \"method\": \"Biochemical fractionation and immunoblotting of insoluble tau from tauopathy brains\",\n      \"journal\": \"Brain pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic comparative biochemistry across multiple disease cohorts, independently replicated\",\n      \"pmids\": [\"10517507\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Using Xenopus oocyte maturation as a microtubule function assay, wild-type four-repeat tau inhibits maturation concentration-dependently while three-repeat tau has no effect. Five FTDP-17 mutants (G272V, ΔK280, P301L, P301S, V337M) failed to inhibit maturation, demonstrating reduced microtubule interaction; R406W behaved nearly like wild-type; S305N inhibited maturation more strongly than wild-type.\",\n      \"method\": \"Xenopus oocyte maturation assay with microinjected recombinant tau proteins\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — intact-cell functional assay with multiple mutants tested, single lab but multiple orthogonal readouts\",\n      \"pmids\": [\"11756436\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"FTDP-17 mutations G272V, ΔK280, and P301L markedly reduce tau's ability to regulate microtubule dynamic instability in living cells, while R406W (outside the microtubule-binding domain) does not significantly alter this regulation, consistent with a loss-of-function mechanism for most tau missense mutations.\",\n      \"method\": \"Microinjection of recombinant tau into cells expressing fluorescent tubulin; live-cell imaging of individual microtubule dynamic instability\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct in-cell functional assay with multiple mutants, orthogonal to in vitro binding assays\",\n      \"pmids\": [\"16495230\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"FTDP-17 mutants V337M and R406W are less susceptible than P301L or wild-type tau to degradation by calpain I, with differences in accessibility of a cleavage site ~100 amino acids from the C-terminus, suggesting some FTDP-17 pathogenesis involves reduced proteolytic tau clearance.\",\n      \"method\": \"In vitro calpain I digestion assay of recombinant mutant tau proteins\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in vitro proteolysis assay, single lab, single method\",\n      \"pmids\": [\"10561502\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Increased neuronal activity (optogenetic and chemogenetic stimulation) stimulates tau release in vitro and enhances tau pathology in vivo; physiological tau released from donor cells can transfer to recipient cells via the extracellular space.\",\n      \"method\": \"Optogenetic and chemogenetic approaches in vitro and in vivo; conditioned medium transfer assay\",\n      \"journal\": \"Nature neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two orthogonal activity-manipulation methods (optogenetic + chemogenetic), in vitro and in vivo validation, single lab\",\n      \"pmids\": [\"27322420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Rab7A regulates tau secretion: deletion of Rab7A decreases tau secretion, while overexpression of dominant-negative Rab7A decreases and constitutively active Rab7A increases tau secretion. Partial co-localization of tau with Rab7A-positive late endosomal structures implicates late endosomes in tau secretion.\",\n      \"method\": \"Rab7A deletion and dominant-negative/constitutively active overexpression in cortical neurons and HeLa cells; tau secretion quantification; co-localization imaging\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function and gain-of-function experiments in two cell systems with imaging, single lab\",\n      \"pmids\": [\"28222213\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CAPON (carboxy-terminal PDZ ligand of nNOS) is a novel tau-binding protein identified by immunoprecipitation/LC-MS. CAPON overexpression induces higher levels of phosphorylated, oligomerized, and insoluble tau and causes caspase3-dependent neuronal death; CAPON deficiency ameliorates AD-related tau pathology.\",\n      \"method\": \"Immunoprecipitation/LC-MS tau interactome screen; CAPON overexpression and knockout in MAPT knock-in mice; biochemical fractionation; caspase3 assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — initial Co-IP/MS identification followed by in vivo genetic loss- and gain-of-function with defined cellular phenotypes\",\n      \"pmids\": [\"31160584\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TIA1 (RNA-binding protein) directly interacts with tau and drives its phase separation at physiological concentrations in the presence of RNA, without artificial crowding agents. Tau oligomers generated during TIA1 co-partitioning are significantly more toxic than aggregates formed with RNA alone or with crowding agents.\",\n      \"method\": \"In vitro phase separation assays with purified tau, RNA, and TIA1; toxicity assays comparing oligomers from different conditions\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with purified components, multiple orthogonal assays (phase separation, oligomer formation, toxicity), single lab\",\n      \"pmids\": [\"33619090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Hyperacetylation of tau by p300 histone acetyltransferase disfavors liquid-liquid phase separation (LLPS) of tau, inhibits heparin-induced aggregation, and impedes LLPS-initiated microtubule assembly, indicating that acetylation prevents LLPS-dependent aggregation but also causes loss-of-function in microtubule stabilization.\",\n      \"method\": \"In vitro acetylation by p300; LLPS assays; thioflavin T aggregation assay; microtubule assembly assay\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with enzymatic modification and multiple functional readouts, single lab\",\n      \"pmids\": [\"29734651\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Aquaporin-4 (AQP4)-driven glymphatic clearance facilitates elimination of extracellular tau from brain to CSF and cervical lymph nodes. AQP4 deletion elevates tau in CSF and markedly exacerbates phosphorylated tau deposition and neurodegeneration in P301S tau transgenic mice.\",\n      \"method\": \"AQP4 knockout in P301S tau transgenic mice; tau quantification in CSF, interstitial fluid, and lymph nodes; immunohistochemistry for tau pathology and neurodegeneration markers\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout with in vivo pathological readouts and CSF/lymph node tracking, single lab but multiple orthogonal methods\",\n      \"pmids\": [\"35212707\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In humanized MAPT knock-in mice expressing all six human tau isoforms, tau humanization significantly accelerates cell-to-cell propagation of AD brain-derived pathological tau, and pathological human tau interacts more efficiently with human tau than with murine tau, revealing species-specific differences in tau seeding.\",\n      \"method\": \"Homologous recombination knock-in; injection of AD brain-derived tau seeds; histological analysis of tau propagation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knock-in model with defined seeding experiments, cross-species comparison, in vivo propagation assay\",\n      \"pmids\": [\"31273083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Oligodendroglial tau pathology propagates along white matter tracts independently of neuronal axons and results in oligodendrocyte cell loss. In contrast, astrocytic tau pathology requires neuronal tau for propagation, revealing cell-type-specific mechanisms of glial tau transmission.\",\n      \"method\": \"Neuronal tau knockdown mouse model; injection of CBD/PSP tau lysates; immunohistochemistry tracking glial tau spread and oligodendrocyte loss\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — novel genetic mouse model with neuronal tau knockdown, in vivo inoculation, defined cellular phenotype, single lab with multiple readouts\",\n      \"pmids\": [\"31826239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BAG3, in cooperation with SYNPO (synaptopodin), facilitates autophagic clearance of phosphorylated tau (p-Ser262) in neuronal processes. Loss of either BAG3 or SYNPO impedes autophagosome-lysosome fusion predominantly in the post-synaptic compartment, leading to accumulation of p-Ser262 tau.\",\n      \"method\": \"shRNA knockdown of BAG3 and SYNPO in primary neurons; autophagy flux assay; immunofluorescence co-localization; biochemical fractionation\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function in primary neurons with specific phospho-tau readout, multiple methods, single lab\",\n      \"pmids\": [\"30744518\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Retromer component VPS35 depletion blocks autophagy resolution and causes marked accumulation of cytoplasmic tau aggregates; VPS35 overexpression has the opposite effect. The autophagy-lysosome axis is identified as the primary mode for clearance of aggregated tau species.\",\n      \"method\": \"Chemical and genetic (VPS35 knockdown/overexpression) approaches in cell models; tau aggregate quantification\",\n      \"journal\": \"Autophagy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — complementary loss- and gain-of-function with defined tau aggregate readout, single lab\",\n      \"pmids\": [\"32960680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Tau oligomers (but not monomers) inhibit anterograde fast axonal transport (FAT) in a squid axoplasm assay; this inhibition requires a small N-terminal stretch termed the phosphatase-activation domain (PAD). Hsp70 preferentially binds tau oligomers and prevents their FAT inhibition.\",\n      \"method\": \"Squid axoplasm assay with monomeric vs. oligomeric/filamentous tau; PAD-deleted tau constructs; Hsp70 co-incubation\",\n      \"journal\": \"Biochemical Society transactions\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted in vitro axoplasm assay with domain-deletion analysis and chaperone rescue, single lab\",\n      \"pmids\": [\"22817713\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"In-cell NMR in HEK-293T cells shows tau predominantly binds microtubules via its MT-binding repeats in the intracellular environment. Disease-associated phosphorylation of tau is rapidly dephosphorylated upon delivery into cells, suggesting an active cellular protection mechanism.\",\n      \"method\": \"In-cell NMR spectroscopy; immunofluorescence co-localization; comparison of in-cell spectrum to in vitro MT-bound tau spectrum\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — in-cell NMR is a rigorous structural method but single lab, single study\",\n      \"pmids\": [\"30587819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Nuclear tau localizes to soluble and chromatin-bound fractions. Tau overexpression or detachment from microtubules increases VGluT1 gene expression. The FTDP-17 P301L mutation impairs this nuclear tau function, representing a loss-of-function mechanism affecting glutamatergic synaptic gene regulation.\",\n      \"method\": \"Subcellular fractionation; overexpression and microtubule-detachment experiments; qRT-PCR and western blot for VGluT1; P301L mutation comparison\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — fractionation with functional gene expression readout, gain-of-function and mutation analysis, single lab\",\n      \"pmids\": [\"30664870\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Endocytosed tau fibrils accumulate in lysosomes of primary astrocytes and neurons, causing lysosomal swelling, deacidification, and ESCRT protein recruitment (but not Galectin-3) consistent with nanoscale membrane damage. Nucleation of cytosolic tau occurs predominantly at the lysosomal membrane, coupling lysosomal escape to cytosolic seeding.\",\n      \"method\": \"Live-cell imaging; STORM superresolution microscopy; ESCRT/Galectin-3 marker recruitment assays in primary cells\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live imaging and superresolution microscopy in primary cells with multiple membrane-damage markers, single lab with orthogonal approaches\",\n      \"pmids\": [\"38781206\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Seed-competent tau monomer (Ms) adopts multiple stable conformational ensembles that each encode distinct tau strains. Ms from AD brain encodes a single strain; Ms from CBD brain encodes three sub-strains that each re-establish all three upon inoculation into cells. Tau monomer conformation thus determines strain identity.\",\n      \"method\": \"Tau monomer purification and inoculation into tau-reporter cell lines (DS9, DS10); inoculation into PS19 tauopathy mice; neuropathological readout\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — cell-based strain propagation assay and in vivo inoculation in mouse model, human patient material, multiple disease sources tested\",\n      \"pmids\": [\"30526844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Acetylmimetic mutations at K321Q and K353Q (KXGS motifs) in tau strongly inhibit prion-like seeded aggregation and intrinsic aggregation of pathogenic P301L/S320F tau double mutant, and alter tau conformational structure to impair Thioflavin S binding, while acetylmimetics at all KXGS sites decrease tau-microtubule interactions.\",\n      \"method\": \"HEK293T cell-based tau aggregation assay; microtubule binding assay; Thioflavin S staining; site-directed mutagenesis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based and in vitro functional assays with multiple site-specific acetylmimetics, single lab\",\n      \"pmids\": [\"34426645\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Tau undergoes liquid-liquid phase separation (LLPS) with DNA, mononucleosomes, and reconstituted nucleosome arrays; low concentrations of tau promote chromatin compaction and protect DNA from digestion. These interactions are driven by tau's binding to linker and nucleosomal DNA and are disrupted by tau hyperphosphorylation.\",\n      \"method\": \"In vitro LLPS assays; DNA protection/digestion assays; chromatin compaction assays; phosphorylation with kinases; NMR and biophysical characterization\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple chromatin substrates, enzymatic phosphorylation reversal, multiple orthogonal biophysical methods, single lab\",\n      \"pmids\": [\"38429335\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"G3BP2, a core stress granule component, directly interacts with tau and inhibits tau aggregation by masking the microtubule-binding region (MTBR) of tau. Loss of G3BP2 in human neurons and brain organoids significantly elevates tau pathology; G3BP2-tau interaction is increased in multiple human tauopathies independent of NFT formation.\",\n      \"method\": \"Co-immunoprecipitation; G3BP2 knockdown in iPSC-derived neurons and brain organoids; in vitro aggregation assay; MTBR mapping; human tauopathy brain analysis\",\n      \"journal\": \"Neuron\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct interaction mapping, loss-of-function in human neurons and organoids, human disease brain validation, multiple orthogonal methods\",\n      \"pmids\": [\"37385246\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Hypoglycemia activates the AMPK-Akt-GSK3 pathway in neurons, leading to increased GSK3α/β activity and tau hyperphosphorylation at Ser262 and Ser396, both in differentiated N2a cells and in rat hippocampus following intracerebroventricular streptozotocin injection.\",\n      \"method\": \"Cell culture glucose deprivation; in vivo intracerebroventricular STZ injection; western blot for phospho-tau, phospho-GSK3, phospho-Akt, phospho-AMPK\",\n      \"journal\": \"Current Alzheimer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo models with pathway-specific readouts, single lab\",\n      \"pmids\": [\"23036024\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Tau-tubulin kinase 1 (TTBK1) directly phosphorylates tau, especially at Ser422, and activates CDK5. TTBK1 transgenic mice crossed with P301L tau mice show accelerated tau accumulation and neuroinflammation, and TTBK1 overexpression induces axonal degeneration in vitro.\",\n      \"method\": \"In vitro kinase assay; TTBK1 transgenic mouse cross with tau mutant mice; in vitro axonal degeneration assay\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro kinase assay plus in vivo transgenic mouse model, single lab\",\n      \"pmids\": [\"24808823\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"MAPT/tau is a microtubule-associated protein that stabilizes axonal microtubules via its repeat-domain binding, regulates microtubule dynamics, undergoes secretion via Rab7A/late endosomal pathway, spreads trans-synaptically in a neuronal activity-dependent manner, is cleared by the glymphatic system and autophagy-lysosome pathway (facilitated by BAG3/SYNPO and retromer/VPS35), undergoes extensive post-translational modifications (phosphorylation, acetylation) that control its microtubule binding, phase separation, chromatin interactions, and aggregation propensity, and can adopt distinct seed-competent monomer conformations that encode different tauopathy strains; disease-causing FTDP-17 mutations reduce microtubule regulatory function and/or shift 3R:4R isoform ratios, while tau oligomers inhibit axonal transport via an N-terminal phosphatase-activation domain and interact pathologically with partners such as TIA1, CAPON, and G3BP2.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"MAPT encodes tau, a microtubule-associated protein whose primary physiological role is to bind and stabilize microtubules and regulate microtubule dynamic instability through its repeat-domain interactions [#3, #4, #17]. In the intracellular environment tau associates predominantly with microtubules via its MT-binding repeats, and disease-associated phosphorylation is rapidly reversed by cellular activity [#17]. Tau also performs nuclear functions, localizing to chromatin and regulating glutamatergic synaptic gene expression such as VGluT1 [#18], and binding linker and nucleosomal DNA to drive chromatin compaction and protect DNA, interactions disrupted by hyperphosphorylation [#22]. FTDP-17 missense mutations and isoform-shifting mutations act largely through loss of microtubule regulatory function or by shifting the 3R:4R isoform ratio, with several mutations additionally promoting filament assembly as a gain of toxic function [#0, #1, #4]; isoform composition itself dictates filament morphology and disease identity, with all six isoforms in AD, 4R tau in CBD/PSP, and 3R tau in Pick's disease [#2]. Post-translational modifications govern tau behavior: acetylation by p300 and acetylmimetics at KXGS motifs suppress phase separation and aggregation while impairing microtubule binding [#10, #21], and kinases including GSK3, TTBK1, and CDK5 drive pathogenic hyperphosphorylation linked to metabolic stress and neurodegeneration [#24, #25]. Tau undergoes liquid-liquid phase separation, which the RNA-binding protein TIA1 promotes in the presence of RNA to generate especially toxic oligomers [#9]. Pathologically, tau adopts distinct seed-competent monomer conformations that encode separate tauopathy strains [#20]; oligomers inhibit fast axonal transport through an N-terminal phosphatase-activation domain [#16] and propagate trans-synaptically in an activity-dependent manner [#6, #12], with cell-type-specific glial transmission mechanisms [#13]. Tau is secreted via a Rab7A-dependent late endosomal route [#7] and cleared by glymphatic (AQP4-dependent) drainage and the autophagy-lysosome pathway facilitated by BAG3/SYNPO and retromer VPS35 [#11, #14, #15]; endocytosed fibrils damage lysosomal membranes and nucleate cytosolic seeding at those membranes [#19]. Additional binding partners CAPON and G3BP2 modulate tau aggregation and toxicity, with G3BP2 protecting tau by masking its microtubule-binding region [#8, #23].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established that FTDP-17 mutations cause disease by impairing tau's core microtubule-binding and assembly-promoting function, defining a loss-of-function axis for tau pathogenesis.\",\n      \"evidence\": \"Microtubule binding/assembly assays with recombinant mutant tau plus patient brain biochemistry\",\n      \"pmids\": [\"9836646\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not establish whether loss of MT function alone is sufficient for neurodegeneration\", \"Did not resolve the gain-of-function aggregation contribution\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Showed that isoform composition determines tauopathy-specific filament morphology, linking the 3R:4R balance to distinct diseases.\",\n      \"evidence\": \"Biochemical fractionation and immunoblotting of insoluble tau across AD, CBD, PSP, and Pick's disease brains\",\n      \"pmids\": [\"10517507\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the structural basis of isoform-specific assembly\", \"Correlative across cohorts, not causal\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Indicated that some FTDP-17 mutations alter tau proteolytic clearance, introducing degradation resistance as a possible pathogenic mechanism.\",\n      \"evidence\": \"In vitro calpain I digestion of recombinant mutant tau\",\n      \"pmids\": [\"10561502\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single in vitro proteolysis assay, single lab\", \"Cellular relevance of calpain cleavage site accessibility not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Unified the loss-of-function and gain-of-toxic-function views by showing mutations either reduce MT interaction or shift toward 4R tau while several also stimulate filament formation.\",\n      \"evidence\": \"In vitro MT binding, heparin-induced filament assembly, and isoform ratio analysis\",\n      \"pmids\": [\"10899436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Heparin-induced assembly is non-physiological\", \"Relative contribution of each mechanism in vivo unresolved\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Confirmed in an intact-cell functional assay that most FTDP-17 mutants lose microtubule-regulatory activity, with mutation-specific exceptions (R406W near-normal, S305N hyperactive).\",\n      \"evidence\": \"Xenopus oocyte maturation assay with microinjected recombinant tau\",\n      \"pmids\": [\"11756436\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Oocyte maturation is an indirect proxy for neuronal MT function\", \"Did not address aggregation\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Directly demonstrated in living cells that FTDP-17 mutations impair tau regulation of microtubule dynamic instability, solidifying the loss-of-function model.\",\n      \"evidence\": \"Live-cell imaging of individual microtubule dynamics after recombinant tau microinjection\",\n      \"pmids\": [\"16495230\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Non-neuronal cell context\", \"Did not connect dynamics defect to downstream neuronal phenotype\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Identified the N-terminal phosphatase-activation domain (PAD) as the element by which tau oligomers, but not monomers, inhibit fast axonal transport, defining a discrete toxic mechanism reversible by Hsp70.\",\n      \"evidence\": \"Squid axoplasm transport assay with monomer/oligomer and PAD-deletion constructs, plus Hsp70 rescue\",\n      \"pmids\": [\"22817713\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Invertebrate axoplasm system\", \"PAD-dependent phosphatase activation not mapped to specific kinase/motor steps in mammalian neurons\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Linked metabolic stress to tau hyperphosphorylation by showing hypoglycemia activates AMPK-Akt-GSK3 signaling to phosphorylate tau at disease sites.\",\n      \"evidence\": \"Glucose deprivation in N2a cells and ICV streptozotocin in rat hippocampus with phospho-specific blotting\",\n      \"pmids\": [\"23036024\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Causal link from GSK3 activity to tau pathology not established by intervention\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established TTBK1 as a direct tau kinase that also activates CDK5 and accelerates tau pathology in vivo, adding a kinase node to tau hyperphosphorylation.\",\n      \"evidence\": \"In vitro kinase assay, TTBK1×P301L transgenic cross, in vitro axonal degeneration\",\n      \"pmids\": [\"24808823\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"TTBK1 overexpression may not reflect endogenous activity levels\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Demonstrated that neuronal activity drives tau release and trans-synaptic transfer, providing a physiological trigger for pathological spread.\",\n      \"evidence\": \"Optogenetic and chemogenetic stimulation in vitro and in vivo with conditioned-medium transfer\",\n      \"pmids\": [\"27322420\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular release machinery not defined here\", \"Did not establish which tau species transfers\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined a Rab7A-dependent late endosomal route for tau secretion, identifying machinery for tau export.\",\n      \"evidence\": \"Rab7A deletion and dominant-negative/constitutively-active overexpression with secretion quantification and co-localization in neurons and HeLa cells\",\n      \"pmids\": [\"28222213\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Partial co-localization leaves other secretion routes open\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Resolved how acetylation tunes tau, showing p300 hyperacetylation blocks LLPS and aggregation but causes loss of microtubule-stabilizing function.\",\n      \"evidence\": \"In vitro p300 acetylation with LLPS, ThT aggregation, and MT assembly readouts\",\n      \"pmids\": [\"29734651\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro only\", \"Site-resolved acetylation effects not mapped here\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Used in-cell NMR to show tau binds microtubules via its repeats in the native cellular environment and that disease phosphorylation is actively reversed, implying a cellular protection mechanism.\",\n      \"evidence\": \"In-cell NMR in HEK-293T with immunofluorescence and comparison to in vitro MT-bound spectra\",\n      \"pmids\": [\"30587819\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab/study\", \"Non-neuronal cells; dephosphorylating enzymes not identified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Established that seed-competent tau monomer conformation encodes tauopathy strain identity, reframing strains as monomer-level conformational information.\",\n      \"evidence\": \"Monomer purification and inoculation into reporter cell lines and PS19 mice using human AD and CBD material\",\n      \"pmids\": [\"30526844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of distinct monomer ensembles not determined\", \"Mechanism converting monomer conformation to strain not resolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified nuclear/chromatin-bound tau as a regulator of glutamatergic synaptic gene expression (VGluT1) impaired by P301L, defining a nuclear loss-of-function mechanism.\",\n      \"evidence\": \"Subcellular fractionation, MT-detachment/overexpression, qRT-PCR with P301L comparison\",\n      \"pmids\": [\"30664870\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of tau-driven transcriptional regulation unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Identified CAPON as a tau-binding protein whose levels drive phosphorylation, oligomerization, and caspase-3-dependent neuronal death, with deficiency ameliorating pathology.\",\n      \"evidence\": \"IP/LC-MS interactome plus CAPON overexpression and knockout in MAPT knock-in mice\",\n      \"pmids\": [\"31160584\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct vs indirect binding interface not mapped\", \"Mechanism linking CAPON to tau phosphorylation unresolved\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Showed humanization of tau accelerates seeded propagation and that human pathological tau seeds human tau more efficiently, revealing species-specific seeding determinants.\",\n      \"evidence\": \"Humanized MAPT knock-in mice injected with AD brain-derived tau seeds\",\n      \"pmids\": [\"31273083\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Sequence determinants of species specificity not pinpointed\", \"Did not resolve which isoforms drive efficiency\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Established BAG3/SYNPO-mediated autophagic clearance of phospho-Ser262 tau in post-synaptic compartments, linking autophagosome-lysosome fusion to tau homeostasis.\",\n      \"evidence\": \"shRNA knockdown of BAG3 and SYNPO in primary neurons with autophagy flux and co-localization assays\",\n      \"pmids\": [\"30744518\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Selectivity for p-Ser262 tau over other species not fully defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Revealed cell-type-specific glial tau transmission: oligodendroglial tau spreads independently of neurons whereas astrocytic tau requires neuronal tau.\",\n      \"evidence\": \"Neuronal tau knockdown mice injected with CBD/PSP lysates, tracked by immunohistochemistry\",\n      \"pmids\": [\"31826239\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of glial uptake/spread not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established the autophagy-lysosome axis as the primary route for clearing aggregated tau, with retromer VPS35 controlling autophagy resolution.\",\n      \"evidence\": \"VPS35 knockdown/overexpression and chemical autophagy modulation in cell models with aggregate quantification\",\n      \"pmids\": [\"32960680\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell-model only\", \"Mechanistic link from retromer to autophagy resolution not detailed\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed TIA1 directly drives physiological-concentration tau phase separation with RNA, generating oligomers more toxic than other aggregation routes, connecting RNP biology to tau toxicity.\",\n      \"evidence\": \"In vitro phase separation with purified tau, RNA, and TIA1 plus comparative toxicity assays\",\n      \"pmids\": [\"33619090\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro reconstitution; cellular validation limited\", \"Toxic oligomer species not structurally defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showed KXGS-motif acetylmimetics inhibit seeded and intrinsic aggregation and alter tau conformation while reducing MT binding, dissecting site-specific acetylation effects.\",\n      \"evidence\": \"HEK293T aggregation and MT binding assays with site-directed acetylmimetic mutants and ThS staining\",\n      \"pmids\": [\"34426645\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Acetylmimetics approximate but do not equal native acetylation\", \"Single lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established AQP4-dependent glymphatic clearance as an in vivo route eliminating extracellular tau to CSF and lymph nodes, with loss exacerbating tau pathology.\",\n      \"evidence\": \"AQP4 knockout in P301S mice with tau tracking in CSF/ISF/lymph nodes and pathology readouts\",\n      \"pmids\": [\"35212707\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define molecular form of tau cleared\", \"Glymphatic vs cellular clearance contributions not partitioned\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified G3BP2 as a direct tau partner that suppresses aggregation by masking the microtubule-binding region, with loss elevating tau pathology in human neurons and organoids.\",\n      \"evidence\": \"Co-IP, MTBR mapping, G3BP2 knockdown in iPSC neurons/organoids, in vitro aggregation, human tauopathy brain analysis\",\n      \"pmids\": [\"37385246\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural detail of MTBR masking not resolved\", \"Regulation of G3BP2-tau interaction in disease unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated that tau binds DNA, mononucleosomes, and nucleosome arrays via LLPS to compact chromatin and protect DNA, with hyperphosphorylation disrupting these chromatin functions.\",\n      \"evidence\": \"In vitro LLPS, DNA protection/digestion, chromatin compaction, enzymatic phosphorylation, and NMR/biophysics\",\n      \"pmids\": [\"38429335\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vitro reconstitution; in vivo chromatin role not established\", \"Genomic targets of nuclear tau not mapped\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Showed endocytosed tau fibrils damage lysosomal membranes and nucleate cytosolic seeding at those membranes, coupling lysosomal escape to seeding.\",\n      \"evidence\": \"Live-cell and STORM imaging with ESCRT/Galectin-3 markers in primary astrocytes and neurons\",\n      \"pmids\": [\"38781206\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular trigger of membrane permeabilization not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How tau's physiological microtubule, nuclear/chromatin, and phase-separation functions are coordinately lost and converted into strain-specific seed-competent aggregates in disease remains unresolved at the structural and pathway-integration level.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structural mechanism linking monomer conformational ensembles to specific clinical strains\", \"Integration of secretion, glymphatic, and autophagic clearance routes in vivo not quantified\", \"Causal hierarchy among phosphorylation, acetylation, and aggregation not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [3, 4, 17]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [3, 4, 17]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [18, 22]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [19]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [6, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [14, 15]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [7]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 1, 2]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [22]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"TIA1\", \"CAPON\", \"G3BP2\", \"Rab7A\", \"BAG3\", \"SYNPO\", \"VPS35\", \"TTBK1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":9,"faith_pct":88.88888888888889}}